Stryker ROE 2006-2019 | SYK
Current and historical return on equity (ROE) values for Stryker (SYK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Stryker ROE for the three months ending June 30, 2019 was 25.98%.
| Stryker ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2019-06-30 | $3.55B | $11.94B | 31.40% |
| 2019-03-31 | $3.52B | $11.69B | 32.96% |
| 2018-12-31 | $3.55B | $11.73B | 35.29% |
| 2018-09-30 | $1.24B | $9.86B | 12.83% |
| 2018-06-30 | $1.08B | $9.46B | 11.05% |
| 2018-03-31 | $1.02B | $9.22B | 10.28% |
| 2017-12-31 | $1.02B | $9.98B | 10.16% |
| 2017-09-30 | $1.78B | $10.43B | 17.92% |
| 2017-06-30 | $1.70B | $10.04B | 17.61% |
| 2017-03-31 | $1.69B | $9.70B | 17.93% |
| 2016-12-31 | $1.65B | $9.55B | 17.91% |
| 2016-09-30 | $1.66B | $9.33B | 18.56% |
| 2016-06-30 | $1.61B | $9.10B | 18.39% |
| 2016-03-31 | $1.62B | $8.81B | 18.85% |
| 2015-12-31 | $1.44B | $8.51B | 17.02% |
| 2015-09-30 | $1.18B | $8.48B | 13.89% |
| 2015-06-30 | $0.93B | $8.51B | 10.96% |
| 2015-03-31 | $0.67B | $8.32B | 7.75% |
| 2014-12-31 | $0.52B | $8.60B | 5.84% |
| 2014-09-30 | $0.64B | $8.62B | 7.17% |
| 2014-06-30 | $0.69B | $9.00B | 7.67% |
| 2014-03-31 | $0.77B | $9.06B | 8.71% |
| 2013-12-31 | $1.01B | $9.05B | 11.55% |
| 2013-09-30 | $0.89B | $8.74B | 10.35% |
| 2013-06-30 | $1.14B | $8.60B | 13.41% |
| 2013-03-31 | $1.25B | $8.46B | 15.01% |
| 2012-12-31 | $1.30B | $8.60B | 15.77% |
| 2012-09-30 | $1.43B | $8.36B | 17.85% |
| 2012-06-30 | $1.40B | $7.95B | 17.98% |
| 2012-03-31 | $1.39B | $8.02B | 17.89% |
| 2011-12-31 | $1.35B | $7.68B | 17.66% |
| 2011-09-30 | $1.24B | $7.56B | 16.54% |
| 2011-06-30 | $1.25B | $7.78B | 16.82% |
| 2011-03-31 | $1.26B | $7.45B | 17.55% |
| 2010-12-31 | $1.27B | $7.17B | 18.25% |
| 2010-09-30 | $1.28B | $7.31B | 18.80% |
| 2010-06-30 | $1.18B | $6.75B | 17.78% |
| 2010-03-31 | $1.15B | $6.67B | 17.82% |
| 2009-12-31 | $1.11B | $6.60B | 17.91% |
| 2009-09-30 | $1.08B | $6.44B | 18.34% |
| 2009-06-30 | $1.12B | $6.06B | 19.69% |
| 2009-03-31 | $1.14B | $5.63B | 19.81% |
| 2008-12-31 | $1.15B | $5.41B | 19.72% |
| 2008-09-30 | $1.15B | $5.75B | 19.71% |
| 2008-06-30 | $1.10B | $6.22B | 19.43% |
| 2008-03-31 | $1.07B | $5.93B | 20.02% |
| 2007-12-31 | $1.02B | $5.38B | 20.54% |
| 2007-09-30 | $0.97B | $5.16B | 20.81% |
| 2007-06-30 | $0.93B | $4.80B | 21.27% |
| 2007-03-31 | $0.87B | $4.49B | 21.27% |
| 2006-12-31 | $0.78B | $4.19B | 20.16% |
| 2006-09-30 | $0.73B | $3.99B | 20.02% |
| 2006-06-30 | $0.66B | $3.77B | 19.34% |
| 2006-03-31 | $0.63B | $3.49B | 19.39% |
| 2005-12-31 | $0.64B | $3.30B | 20.94% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $80.642B | $13.601B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $145.598B | 26.57 |
| Medtronic (MDT) | Ireland | $145.585B | 20.43 |
| Boston Scientific (BSX) | United States | $53.170B | 25.79 |
| Baxter (BAX) | United States | $44.852B | 27.20 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $32.725B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $28.438B | 18.20 |
| Coloplast (CLPBY) | Denmark | $25.747B | 41.10 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.481B | 0.00 |
| Terumo (TRUMY) | Japan | $24.495B | 30.57 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $20.928B | 0.00 |
| ResMed (RMD) | United States | $18.924B | 36.06 |
| Sunny Optical Technology (SNPTF) | China | $16.014B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.234B | 54.86 |
| Insulet (PODD) | United States | $9.431B | 558.86 |
| Perrigo (PRGO) | Ireland | $7.400B | 13.63 |
| Canopy Growth (CGC) | Canada | $7.222B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.830B | 20.36 |
| Haemonetics (HAE) | United States | $6.455B | 48.71 |
| William Demant Holdings (WILYY) | Denmark | $5.988B | 0.00 |
| GN STORE NORD (GNNDY) | Denmark | $5.344B | 27.61 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $4.296B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $4.002B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.680B | 0.00 |
| Neogen (NEOG) | United States | $3.490B | 58.40 |
| NuVasive (NUVA) | United States | $3.398B | 27.09 |
| ICU Medical (ICUI) | United States | $3.237B | 21.00 |
| Hutchison China MediTech (HCM) | Hong Kong, SAR China | $2.634B | 0.00 |
| Quidel (QDEL) | United States | $2.510B | 24.93 |
| Agios Pharmaceuticals (AGIO) | United States | $1.982B | 0.00 |
| National Vision Holdings (EYE) | United States | $1.877B | 40.51 |
| Cardiovascular Systems (CSII) | United States | $1.670B | 0.00 |
| Aphria (APHA) | $1.242B | 0.00 | |
| VAREX IMAGING (VREX) | United States | $1.124B | 25.90 |
| AtriCure (ATRC) | United States | $1.059B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.867B | 14.10 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.854B | 21.78 |
| NanoString Technologies (NSTG) | United States | $0.787B | 0.00 |
| Omeros (OMER) | United States | $0.759B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.734B | 19.29 |
| PetIQ (PETQ) | United States | $0.725B | 17.13 |
| LeMaitre Vascular (LMAT) | United States | $0.689B | 40.82 |
| Cerus (CERS) | United States | $0.624B | 0.00 |
| Surmodics (SRDX) | United States | $0.621B | 118.00 |
| MacroGenics (MGNX) | United States | $0.560B | 0.00 |
| Quanterix (QTRX) | United States | $0.548B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.530B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.523B | 24.23 |
| Owens & Minor (OMI) | United States | $0.459B | 13.76 |
| Meridian Bioscience (VIVO) | United States | $0.427B | 13.32 |
| Utah Medical Products (UTMD) | United States | $0.354B | 25.91 |
| Zynex (ZYXI) | United States | $0.346B | 36.76 |
| BioLife Solutions (BLFS) | United States | $0.339B | 104.19 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.327B | 0.00 |
| Bovie Medical (APYX) | United States | $0.234B | 0.00 |
| United Health Products (UEEC) | United States | $0.208B | 0.00 |
| Vapotherm (VAPO) | United States | $0.177B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.153B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.147B | 0.00 |
| Female Health (VERU) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.133B | 9.32 |
| Liberty Health Sciences (LHSIF) | Canada | $0.104B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.097B | 0.00 |
| Chimerix (CMRX) | United States | $0.088B | 0.00 |
| Nephros (NEPH) | United States | $0.087B | 0.00 |
| United-Guardian (UG) | United States | $0.084B | 19.82 |
| MTech Acquisition (KERN) | United States | $0.063B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.053B | 0.00 |
| ImmuCell (ICCC) | United States | $0.040B | 0.00 |
| Surface Oncology (SURF) | United States | $0.039B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.020B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.018B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.013B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.010B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.007B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.005B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.003B | 0.00 |
